Please assess the completion status of the following clinical trial:

Trial Title: JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men will be eligible for the study if:~1. age at least 45 years~2. report symptoms of discomfort or pain in the pelvic region during at least 3 of the previous 6 months~3. total score of at least 12 (out of 43) points on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) at both a screening and randomization visit~4. IPSS score of at least 8 points 5 tenderness on light palpation of the prostate~6. prostate size estimated to be at least 30cc on digital rectal examination~Exclusion Criteria:~Participants are excluded if~1. prior treatment with dutasteride or finasteride. Alpha blocker therapy within 3 months of randomization.~2. documented urinary tract infection (\>105 colony forming units per ml of a recognized uropathogen)~3. history of renal failure (or calculated creatinine clearance of \< 60 ml/min)~4. symptomatic genital herpes in the last 3 months.~5. unilateral orchalgia without pelvic symptoms~6. a history of active urogenital cancer~7. active urethral stricture.~8. surgery of the lower urinary tract (not including simple diagnostic cystoscopy) in the previous 6 months (including TURP, bladder neck incision, bladder tumor resection, urethrotomy).~9. History of alcohol abuse~10. neurologic disease affecting voiding or the bladder~11. Psychiatric condition that would make it difficult (in opinion of investigator) for patient to participate in the study~12. Other acute or chronic medical condition that would make it difficult (in opinion of investigator) for patient to participate in the study

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Jaylyn (Type: EXPERIMENTAL): Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).